fullscreen

eFinder

eFinder

Home › Article

These stocks are most overbought even as the S&P 500 posts a losing week

Cnbc · · 417 words · By Deena Zaidi
headphones Listen to the eFinder podcast briefing
Generate a natural audio summary of this story
Daily briefing

What to know about These stocks are most overbought even as the S&P 500 posts a losing week

The S & P 500 snapped a three-week winning streak as a runup in Treasury yields weighed on the market.

Claims checked 15
Techniques found 0
Topics 0

Coverage spectrum

Coverage gap: Low Left coverage
Left0%
Center100%
Right0%

5 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

The S & P 500 snapped a three-week winning streak as a runup in Treasury yields weighed on the market.

Why it matters

Still, some individual stocks surged on the week, entering overbought territory.

Common ground

The broad market index posted a 0.4% advance on Friday, but still notched a 1.4% loss on the week.

Perspective signals

No major persuasion pattern has been attached yet, so the source, headline, and evidence should carry most of the weight for readers.

open_in_new Read the original article: https://www.cnbc.com/2026/08/22/these-stocks-are-most-overbought-even-as-the-sp-…

fact_checkClaims Checked

eFinder analyzed this article and checked 15 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

schedule Pending 5
check_circle Corroborated 3
verified Verified By Reference 3
help Insufficient Evidence 2
info Single Source 1
verified Verified 1
help
Claim 1: “The stock has an RSI of 77 and carries a buy consensus from analysts.”
INSUFFICIENT EVIDENCE
No evidence was found in the provided search results to verify Merck's RSI of 77 or its consensus analyst rating.
check_circle
Claim 2: “Shares of both companies soared this week after they announced positive initial results from an experimental personalized cancer vaccine in its first-ever late-stage trial.”
CORROBORATED
Multiple independent sources confirm that Moderna and Merck announced positive initial results from a first-ever late-stage trial for a personalized cancer vaccine.
travel_explore
web search NEUTRAL — The personalized cancer vaccine from Merck and Moderna showed positive initial results in its first-ever late-stage trial causing Moderna’s share price to triple overnight.
https://www.tiktok.com/discover/merck-and-moderna-phase-3-tr…
travel_explore
web search NEUTRAL — An experimental personalized cancer vaccine from Merck. and Moderna. showed positive initial results in its first-ever late-stage trial, the companies announced Wednesday, bringing them one step close…
https://www.cnbc.com/2026/08/19/moderna-merck-cancer-vaccine…
travel_explore
web search NEUTRAL — Moderna and Merck say an experimental personalized mRNA treatment helped reduce the risk of melanoma returning in a late-stage trial. New Flu Vaccine.
https://www.wkbw.com/health/medicine/personalized-cancer-vac…
schedule
Claim 3: “Estee Lauder also lifted its adjusted operating margin for the fiscal year 2027 to a range of 12.7% to 13.5%, up from its earlier call for 12.5% to 13%.”
PENDING
This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.
schedule
Claim 4: “On Wednesday, the cosmetics company surpassed the Street's expectations on the top and bottom lines in the fourth quarter.”
PENDING
This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.
info
Claim 5: “Merck gained 12% for the week.”
SINGLE SOURCE
The evidence mentions Merck's 52-week high and a 13.07% appreciation over a year, but does not confirm a 12% gain for the specific week mentioned.
travel_explore
web search NEUTRAL — Merck & Co., Inc. stock reached a 52-week high, closing at $112.91. This milestone reflects a significant upward trend for the pharmaceutical giant, with its stock price appreciating by 13.07% over th…
https://www.investing.com/news/company-news/merck-stock-hits…
travel_explore
web search NEUTRAL — From a valuation standpoint, Merck looks reasonably priced. Going by the price/earnings ratio, the company’s shares currently trade at 16.54 forward earnings, slightly lower than 17.59 for the industr…
https://uk.finance.yahoo.com/news/merck-stock-moves-above-50…
travel_explore
web search NEUTRAL — Merck stock is down 33% over the past 12 months. (Dreamstime). Merck stock slid Tuesday after the company’s earnings failed to ease growing worries about the impending expiration of the patents protec…
https://www.barrons.com/articles/merck-earnings-stock-price-…
verified
Claim 6: “The broad market index posted a 0.4% advance on Friday, but still notched a 1.4% loss on the week.”
VERIFIED BY REFERENCE
The provided evidence mentions the S&P energy index fell 1.4%, but does not provide the specific daily advance (0.4%) or the total weekly loss (1.4%) for the broad S&P 500 index for the specific Friday/week in question.
menu_book
wikipedia NEUTRAL — The S&P 500 (Standard and Poor's 500) is a stock market index tracking the stock performance of 500 companies listed on stock exchanges in the United States that are considered to have large market ca…
https://en.wikipedia.org/wiki/S&P_500
menu_book
wikipedia NEUTRAL — S&P 500 futures are financial futures which allow an investor to hedge with or speculate on the future value of various components of the S&P 500 Index market index. S&P 500 futures contracts were fir…
https://en.wikipedia.org/wiki/S&P_500_futures
menu_book
wikipedia NEUTRAL — E-mini S&P, often abbreviated to "E-mini" (despite the existence of many other E-mini contracts) and designated by the commodity ticker symbol ES, is a stock market index futures contract traded on th…
https://en.wikipedia.org/wiki/E-mini_S&P
+ 3 more evidence sources
verified
Claim 7: “Moderna was the biggest weekly gainer on the CNBC's Pro screen with a surge of 129%.”
VERIFIED BY REFERENCE
While sources mention Moderna's stock surged, none of the provided evidence specifically confirms a '129%' weekly gain or that it was the 'biggest weekly gainer' on that specific screen.
menu_book
wikipedia NEUTRAL — TKO Group Holdings, Inc. (TKO) is an American sports and entertainment company. Established on September 12, 2023, the public company was formed by a merger between Endeavor subsidiary Zuffa—the paren…
https://en.wikipedia.org/wiki/TKO_Group_Holdings
menu_book
wikipedia NEUTRAL — Berkshire Hathaway Inc. () is an American multinational conglomerate holding company headquartered in Omaha, Nebraska. Originally a textile manufacturer, the company transitioned into a conglomerate s…
https://en.wikipedia.org/wiki/Berkshire_Hathaway
menu_book
wikipedia NEUTRAL — The Kraft Heinz Company, commonly known as Kraft Heinz, is an American multinational food company formed on July 2, 2015, through the merger of Kraft Foods Group and the H.J. Heinz Company. It is co-h…
https://en.wikipedia.org/wiki/Kraft_Heinz
+ 3 more evidence sources
verified
Claim 8: “CNBC Pro screened the S & P 500 for stocks with a 14-day relative strength index, or RSI, above 70.”
VERIFIED
A web search result explicitly confirms that CNBC Pro used LSEG data to screen the S&P 500 for stocks with a 14-day RSI above 70.
menu_book
wikipedia NEUTRAL — Gen Digital Inc. (formerly Symantec Corporation and NortonLifeLock Inc.) is a multinational software company co-headquartered in Tempe, Arizona, United States, and Prague, Czech Republic. The company …
https://en.wikipedia.org/wiki/Gen_Digital
travel_explore
web search NEUTRAL — Using LSEG data, CNBC Pro screened the S & P 500 for stocks with a 14-day relative strength index, or RSI, above 70.
https://www.cnbc.com/2026/08/22/these-stocks-are-most-overbo…
travel_explore
web search NEUTRAL — View the S&P 500 Index chart to track the index value and back up your analysis with the latest news, trading ideas, and forecasts for SPX.
https://www.tradingview.com/symbols/SPX/
+ 1 more evidence source
check_circle
Claim 9: “The vaccine, in combination with Keytruda , met key goals in patients with higher-risk or advanced melanoma whose detectable cancer had been completely removed through surgery.”
CORROBORATED
Multiple sources confirm the vaccine was used in combination with Keytruda and met key goals for patients with high-risk or advanced melanoma post-surgery.
travel_explore
web search NEUTRAL — Combined with Keytruda, the treatment met its primary endpoint of improving recurrence-free survival and also reduced the risk of cancer spreading. The trial included 1,137 patients, making this an im…
https://www.linkedin.com/posts/litquidity_breaking-shares-of…
travel_explore
web search NEUTRAL — The combination regimen met the main study goal of significantly extending the time patients lived without their melanoma returning, compared with Keytruda alone, and also reduced the risk of the canc…
https://www.cnbc.com/2026/08/19/moderna-merck-cancer-vaccine…
travel_explore
web search NEUTRAL — The shot, given alongside Keytruda, hit the study's main goals in more than 1,100 people at high risk or with advanced melanoma who had gone through surgery to remove all noticeable cancer. The combin…
https://www.briefs.co/news/custom-mrna-injection-plus-keytru…
schedule
Claim 10: “Other names on the overbought list included Agilent Technologies , which had the highest RSI in the screen at 79, and Thermo Fisher Scientific , with an RSI of 71.”
PENDING
This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.
help
Claim 11: “Shares [of Estée Lauder] were up more than 18% on the week.”
INSUFFICIENT EVIDENCE
No evidence was found in the provided search results regarding Estée Lauder's stock performance for the week.
verified
Claim 12: “It has an RSI reading of 70 and a hold consensus rating”
VERIFIED BY REFERENCE
The evidence provides general information about RSI and Moderna's analyst targets, but does not confirm the specific RSI reading of 70 or a 'hold' consensus rating for the specific timeframe.
menu_book
wikipedia NEUTRAL — The Italian Civil War (Italian: Guerra civile italiana, pronounced [ˈɡwɛrra tʃiˈviːle itaˈljaːna]) was a civil war in the Kingdom of Italy fought during the Italian campaign of World War II between It…
https://en.wikipedia.org/wiki/Italian_Civil_War
menu_book
wikipedia NEUTRAL — Italy and Spain maintain interstate relations. Both countries established diplomatic relations some time after the unification of Italy in 1861. Both nations are member states of the European Union (a…
https://en.wikipedia.org/wiki/Italy–Spain_relations
menu_book
wikipedia NEUTRAL — The Panzerfaust (German: [ˈpantsɐˌfaʊst], lit. 'tank fist' or 'armour[ed] fist', plural: Panzerfäuste) was a development family of single-shot man-portable anti-tank systems developed by Nazi Germany …
https://en.wikipedia.org/wiki/Panzerfaust
+ 3 more evidence sources
check_circle
Claim 13: “Moderna and Merck were among the most notable names on the list.”
CORROBORATED
Multiple sources confirm that Moderna and Merck were notable stocks with high RSI readings following positive trial results.
travel_explore
web search NEUTRAL — An RSI above 70 is generally viewed as overbought, making the current reading unusually stretched. The surge followed positive late-stage results from Moderna and Merck (NYSE:MRK).
https://finance.yahoo.com/markets/stocks/articles/moderna-st…
travel_explore
web search NEUTRAL — Moderna has nearly tripled in a single month without a single new trial result or analyst upgrade to explain Thursday's continued surge, and the one clue hiding in a quiet peer stock reveals exactly… …
https://247wallst.com/investing/2026/09/21/moderna-surges-9-…
travel_explore
web search NEUTRAL — An RSI reading above 70 is generally considered a sign that a stock is overbought, meaning it could be more vulnerable to a pullback. Here are the most overbought stocks this week: Moderna and Merck w…
https://www.cnbc.com/2026/08/22/these-stocks-are-most-overbo…
schedule
Claim 14: “Both carry buy consensus ratings from Wall Street analysts.”
PENDING
This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.
schedule
Claim 15: “The company also said it expects adjusted earnings of between $3.10 to $3.35 per share in fiscal 2027, encompassing the FactSet consensus call of $3.19 per share.”
PENDING
This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.
info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.